Significant progress been made in personalized therapies for the management of advanced stage CRC patients based on their biomarker status but a deeper understanding of tumor heterogeneity leading to resistance is needed to identify more effective and personalized treatment options.

Click here to read more:

https://www.smartanalyst.com/wp-content/uploads/2022/09/ESMO-Post-final.pdf